Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Total Current Liabilities (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Total Current Liabilities for 7 consecutive years, with $83.2 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 22.79% to $83.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $83.2 million through Dec 2025, up 22.79% year-over-year, with the annual reading at $83.2 million for FY2025, 22.79% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $83.2 million at Kymera Therapeutics, up from $71.6 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $110.1 million in Q1 2021, with the low at $54.6 million in Q2 2023.
  • Average Total Current Liabilities over 5 years is $78.2 million, with a median of $77.4 million recorded in 2025.
  • The sharpest move saw Total Current Liabilities plummeted 37.6% in 2023, then surged 40.87% in 2025.
  • Over 5 years, Total Current Liabilities stood at $92.5 million in 2021, then dropped by 22.91% to $71.3 million in 2022, then increased by 20.11% to $85.7 million in 2023, then fell by 20.92% to $67.8 million in 2024, then rose by 22.79% to $83.2 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $83.2 million, $71.6 million, and $87.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.